(Updated - October 8, 2019 5:45 AM EDT)(updated to add analyst comment)Goldman Sachs analyst Paul Choi downgraded Nektar Therapeutics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE